Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 880-886

  Sparano, Joseph A ^a   Speyer, James ^a   Gradishar, William J ^a   Liebes, Leonard ^a   Sridhara, Rajeshwari ^a   Mendoza, Sandra ^a   Fry, David ^a   Egorin, Merrill J ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RAZOXANE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0032977942     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.880     Document Type: Article

References (31)

1. Honig SF: Treatment of metastatic disease: Hormonal and chemotherapy, in Harris JR, Lippman ME, Morrow M, et al (eds): Disease of the Breast. Philadelphia, PA, Lippincott-Raven, 1996
2. A'Hern RPA, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993
3. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
4. Dombemowsky P, Gehl J, Boesgaard M, et al: Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23:23-27, 1996 (suppl 11)
5. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
6. Amadori D, Frassinetti GL, Zoli W, et al: Phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin Oncol 23:16-22, 1996 (suppl 11)
7. Schwartsmann G, Menke CH, Caleffi M, et al: Phase II trial of Taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:126a, 1996 (abstr 168)
8. Sledge GW Jr, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin versus paclitaxel versus doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997 (abstr 2)
9. Cazap E, Ventriglia E, Rubio G, et al: Taxol plus doxorubicin in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 15:146a, 1996 (abstr 248)
10. Sparano JA, Hu P, Rao RM, et al: Phase II trial of doxorubicin plus paclitaxel plus G-CSF in metastatic breast cancer: An Eastern Cooperative Oncology Group trial (E4195). Breast Cancer Res Treat 46:23, 1997 (abstr 3)
11. Gianni L, Vigano L, Locatelli A, et al: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915, 1997
12. Holmes FA, Madden T, Newman RA, et al: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721, 1996
13. Berg SL, Cowan KH, Balis FM, et al: Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143-145, 1994
14. Solis Recendez MG, Grossin F, Cichat F, et al: Drug interactions between Taxol and adriamycin in mice: Difference of ADR incorporation according to the schedule of administration. Proc Am Assoc Cancer Res 72:372a, 1996 (abstr 2540)
15. Colombo T, Gonzalez Paz O, Zucchetti M, et al: Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol 7:801-805, 1996
16. Jones RB, Holland JF, Bhardwaj S, et al: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 5:172-177, 1987
17. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
18. Swain S, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
19. Swain S, Whaley FS, Gerber MC, et al: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333-1340, 1997
20. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
21. Tjuljandin SA, Doig RG, Sobol MM, et al: Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res 50:5095-5101, 1990
22. Hochster H, Liebes L, Wadler S, et al: Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725-1730, 1992
23. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
24. D'Argenio DZ, Schumitsky A: ADAPT II User's Guide. Los Angeles, CA, Biomedical Simulations Resource, University of Southern California, 1990
25. Yeh KC, Kwan KC: A comparison of numerical integrating algorithms by trapezoidal, LaGrange and spline approximation. J Pharmacokinet Biopharm 6:79-98, 1978
26. Rocci ML, Jusko WJ: LAGRAN program for area and moments in pharmacokinetics analysis. Comput Prog Biomed 16:203-216, 1983
27. Liesmann J, Belt R, Haas C, et al: Phase I evaluation of ICRF-187 by 48-hour continuous infusion. Cancer 47:1959-1962, 1981
28. Von Hoff DD, Howser D, Lewis BJ, et al: Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 65:249-252, 1981
29. Holcenberg JS, Tutsch KD, Earhart RH, et al: Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 70:703-709, 1986
30. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
31. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 388)